Results 71 to 80 of about 407,671 (265)

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

The effects of dietary Zhumeria majdae extract on growth indices, hematology and immunology of catfish Pangasianodon hypophthalmus [PDF]

بوم‌شناسی آبزیان, 2013
Low survival at early stages of life is of great concern for fish culturists. Considering the effects of herbal immunostimulants on innate immune response and growth improvement of aquatic animals, the impacts of a native herb of Hormozgan province named
Mohammad Hadi Rezaei, Iman Sourinejad, Siavash Soltanian, Morteza Yousefzadi   +3 more
doaj  

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation

Journal of Blood Medicine, 2016
Shosaku Nomura,1 Yoshinobu Maeda,2 Kazuyoshi Ishii,1 Yuta Katayama,3 Hideo Yagi,4 Naoto Fujishima,5 Shuichi Ota,6 Masato Moriyama,7 Takayuki Ikezoe,8 Yasuhiko Miyazaki,9 Kunio Hayashi,10 Shinya Fujita,1 Atsushi Satake,1 Tomoki Ito,1 Taiichi Kyo,3 Mitsune
Nomura S, Maeda Y, Ishii K, Katayama Y, Yagi H, Fujishima N, Ota S, Moriyama M, Ikezoe T, Miyazaki Y, Hayashi K, Fujita S, Satake A, Ito T, Kyo T, Tanimoto M   +15 more
doaj  

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Editorial: Women in Science—Hematology 2021

Frontiers in Medicine, 2022
Eleni Gavriilaki, Chien-Ling Huang, Lalitha Nayak   +2 more
doaj   +1 more source

The Danish National Chronic Lymphocytic Leukemia Registry

Clinical Epidemiology, 2016
Caspar da Cunha-Bang,1 Christian Hartmann Geisler,2 Lisbeth Enggaard,3 Christian Bjørn Poulsen,4 Peter de Nully Brown,2 Henrik Frederiksen,5 Olav Jonas Bergmann,6 Elisa Jacobsen Pulczynski,7 Robert Schou Pedersen,8 Linda Højberg Nielsen,9 ...
da Cunha-Bang C, Geisler CH, Enggaard L, Poulsen CB, de Nully Brown P, Frederiksen H, Bergmann OJ, Pulczynski EJ, Pedersen RS, Nielsen LH, Christiansen I, Niemann CU   +11 more
doaj  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

وضعیت سیستم ثبت اطلاعات خون‌شناسی در آزمایشگاه‌های بیمارستان‌های آموزشی درمانی وابسته به دانشگاه علوم پزشکی شهید بهشتی

مدیریت اطلاعات سلامت, 2009
Introduction: Hematology section provides valuable information for diagnosis and treatment of patients to improve the health of them. In this regard Hematology Information System led to deliver produced information accurately and timely.
Farkhondeh Asadi, Hamid Moghaddasi, Zahra Mastaneh   +2 more
doaj  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source